2011
DOI: 10.1155/2011/963159
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Despite the recent advances in the management of cervical cancer using cisplatin-based concurrent chemoradiotherapy, substantial treatment failure still occurs, especially in advanced-stage patients and early-stage cervical cancer patients with high-risk prognostic factors. Therefore, efforts to further improve the survival and quality of life of these patients are necessary. Nedaplatin (cis-diammine-glycoplatinum), a derivative of cisplatin, was developed with the aim of producing a treatment with a similar … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
10
0
1

Year Published

2012
2012
2023
2023

Publication Types

Select...
7
1

Relationship

2
6

Authors

Journals

citations
Cited by 15 publications
(12 citation statements)
references
References 42 publications
1
10
0
1
Order By: Relevance
“…However, nedaplatin (cis-diammine-glycoplatinum), a derivative of cisplatin, was developed by the Shionogi Pharmaceutical Company in Japan with the aim of reducing renal toxicity but maintaining efficacy, compared with cisplatin [13]. The G3 chronic GI complication rate of 13% in our study is similar to that observed with the use of other postoperative concurrent platinum-based chemotherapy and WPRT for cervical cancer [14, 15].…”
Section: Discussionsupporting
confidence: 75%
“…However, nedaplatin (cis-diammine-glycoplatinum), a derivative of cisplatin, was developed by the Shionogi Pharmaceutical Company in Japan with the aim of reducing renal toxicity but maintaining efficacy, compared with cisplatin [13]. The G3 chronic GI complication rate of 13% in our study is similar to that observed with the use of other postoperative concurrent platinum-based chemotherapy and WPRT for cervical cancer [14, 15].…”
Section: Discussionsupporting
confidence: 75%
“…This drug was developed with the aim to avoid the nephrotoxicity and gastrotoxicity of cisplatin while maintaining the same efficacy (Mabuchi and Kimura, 2010). It presents two ammonia and a glycolate ligand which forms a five-membered ring with the platinum ion.…”
Section: Nedaplatinmentioning
confidence: 99%
“…Standard adjuvant treatment after radical hysterectomy in our institution comprises external beam pelvic radiotherapy plus concurrent chemotherapy (CCRT), as reported previously [20][21][22]24]. Patients who declined concurrent chemotherapy or who suffered from cervical cancer before April 1999 were treated with pelvic radiotherapy alone.…”
Section: Postoperative Radiotherapymentioning
confidence: 99%